Description:
CAT-00390_aHIV[rh10-1074LS] is a rhesus IgG1 chimeric version of the broadly neutralizing anti-HIV monoclonal antibody 10-1074, engineered with LS mutations (M428L/N434S) in the Fc region to prolong in vivo half-life via enhanced neonatal Fc receptor (FcRn) binding. This antibody targets the V3 glycan patch on the HIV-1 Envelope glycoprotein (Env), a region enriched in high-mannose glycans and critical for viral infectivity and neutralization sensitivity.

The rhesus Fc backbone ensures functional compatibility with Fcγ receptors in nonhuman primate (NHP) models, making this antibody suitable for preclinical studies of HIV prevention, therapeutic efficacy, and viral reservoir reduction. The LS-enhanced half-life supports longitudinal study designs requiring infrequent dosing.

Key Features:
LS-Modified Fc (M428L/N434S): Enables extended serum persistence through improved FcRn recycling.
Rhesus IgG1 Format: Designed for optimal effector function and pharmacodynamics in macaque models.
High Potency bNAb: Retains the neutralization breadth and potency of parental 10-1074, targeting the V3 glycan epitope.
Validated Epitope: Recognizes a conserved glycan-dependent region across multiple HIV-1 strains.
 

Applications:
Passive immunization for HIV prevention in rhesus macaques
Pharmacokinetic and half-life studies using LS-enhanced antibodies
Combination antibody regimens for viral suppression or cure strategies
Preclinical validation of antibody-based interventions targeting the V3 glycan site

Usage Notes:
This antibody is supplied as an unconjugated rhesus IgG1 and is optimized for in vivo use in macaque models. The LS modifications support extended dosing intervals (e.g., every 2–4 weeks), allowing for more efficient experimental timelines and reduced handling in long-term studies.